Today, Monday, October 11, AstraZeneca revealed more positive results regarding the trial of a mixture of antibodies to the Corona virus, according to the Medical Express website.
The company said in a statement that the drug, which is made from a mixture of two antibodies, achieved a “statistically significant decrease in cases of acute coronavirus infection or death” in patients who were not hospitalized and with symptoms between mild to moderate, as they are undergoing treatment. , known as AZD7442, has been approved for Phase III or final clinical trials to evaluate its safety and efficacy.
And “AstraZeneca” revealed that the drug reduced the risk of severe coronavirus infection or death by 50% in patients who showed symptoms for 7 days or less, achieving the main goal of the experiment.
Hugh Montgomery, lead investigator of the trial, explained: “With serious cases of coronavirus infections continuing to persist around the world, there is a great need for new treatments such as AZD7442 that can be used to protect vulnerable populations, and can also help prevent progression to serious disease.”
He continued, “These positive results show that a comfortable intramuscular dose of AZD7442 can play an important role in helping to combat this devastating epidemic.”
“Early intervention with our antibodies can significantly reduce the progression of severe disease, with protection lasting more than 6 months,” said Maine Bangalos, executive vice president of research and development for biopharmaceuticals at AstraZeneca. 90% of them are people at high risk of severe coronavirus infection.
And the Medical Express website explained, the “Corona” vaccine developed by “AstraZeneca”, with the University of Oxford, helped enable the rapid British vaccination campaign against “Corona”, adding that the company will discuss the data with health authorities without going into details.
